Impact of Adjuvant Chemotherapy Cycles on Prognosis of Resectable Stomach Cancer: A Retrospective Analysis

  • Zhang, Wen-Ying (Department of Gastroenterology, Changhai Hospital, Second Military Medical University) ;
  • Zhang, Wen-Jun (Department of Gerontology, Changhai Hospital, Second Military Medical University) ;
  • Bai, Yu (Department of Gastroenterology, Changhai Hospital, Second Military Medical University) ;
  • Yuan, Hai-Hua (Department of Oncology, No. 3 People's Hospital, School of Medicine, Shanghai Jiaotong University) ;
  • Liu, Feng (Department of Oncology, No. 3 People's Hospital, School of Medicine, Shanghai Jiaotong University) ;
  • Gao, Jun (Department of Gastroenterology, Changhai Hospital, Second Military Medical University) ;
  • Gong, Yan-Fang (Department of Gastroenterology, Changhai Hospital, Second Military Medical University) ;
  • Jiang, Bin (Department of Oncology, No. 3 People's Hospital, School of Medicine, Shanghai Jiaotong University)
  • Published : 2013.01.31


Aims: The aim of this study was to investigate the effects of adjuvant chemotherapy cycles on the prognosis of patients with post-operative stomach cancer through retrospective analysis. Methods: A total of 128 patients with gastric cancer who underwent gastrectomy, followed by adjuvant chemotherapy consisting of epirubicin, cisplatin or oxaliplatin, leucovorin, and 5-fluorouracil, according to a defined schedule, were divided into three groups according to the number of chemotherapy cycles: Group I (<6 cycles); Group II (6 cycles); and Group III (>6 cycles). Results: The 5-year overall survival (OS) was 20.8% in Group I, 45.0% in Group II, and 42.9% in Group III, with a median follow-up of 43 months. The 5-year relapse-free survival (RFS) was 15.1% in Group I, 40% in Group II, and 40% in Group III. The OS and RFS in Groups II and III were significantly better than in Group I (OS, p = 0.002 and p=0.003; RFS, P<0.001 and P=0.002). There was no difference in OS (p = 0.970) or in RFS (p = 0.722) between Groups II and III. Multivariate Cox hazard analysis determined that the number of adjuvant chemotherapy cycles was an independent factor that influenced OS and RFS. Conclusion: Six cycles of adjuvant chemotherapy gave encouraging outcomes in patients with resectable gastric cancer. Further prospective randomized controlled investigations are warranted in a multi-center setting.


Supported by : Shanghai Science and Technology Committee Foundation


  1. Neri B, Pantaleo P, Giommoni E, et al (2007). Oxaliplatin, 5-fluorouracil/leucovorin and epirubicin as first-line treatment in advanced gastric carcinoma: a phase II study. Br J Cancer, 96, 1043-6.
  2. Oba K (2009). Efficacy of adjuvant chemotherapy using tegafur-based regimen for curatively resected gastric cancer: update of a meta-analysis. Int J Clin Oncol, 14, 85-9.
  3. Oh SC (2012). Update of adjuvant chemotherapy for resected gastric cancer. J Gastric Cancer, 12, 3-6.
  4. Oken MM, Creech RH, Tormey DC, et al (1982). Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol, 5, 649-55.
  5. Okines A, Verheij M, Allum W, et al (2010). Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol, 21, v50-4.
  6. Panzini I, Gianni L, Fattori PP, et al (2002). Adjuvant chemotherapy in gastric cancer: a meta-analysis of randomized trials and a comparison with previous meta-analyses. Tumori, 88, 21-7.
  7. Paoletti X, Oba K, Burzykowski T, et al (2010). Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis. JAMA, 303, 1729-37.
  8. Sakuramoto S, Sasako M, Yamaguchi T, et al (2007). Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med, 357, 1810-20.
  9. Saletti P, Berthold D, Ghielmini M, et al (2007). Adjuvant chemotherapy (ECF regimen) for patients with gastric adenocarcinoma. Hepatogastroenterology, 54, 969-72.
  10. Sasako M, Sakuramoto S, Katai H, et al (2011). Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J Clin Oncol, 29, 4387-93.
  11. Zhang CX, Huang S, Xu N, et al (2007). Phase II study of epirubicin plus oxaliplatin and infusional 5-fluorouracil as first-line combination therapy in patients with metastatic or advanced gastric cancer. Anticancer Drugs, 18, 581-6.
  12. Zhao SL, Fang JY (2008). The role of postoperative adjuvant chemotherapy following curative resection for gastric cancer: a meta-analysis. Cancer Invest, 26, 317-25.
  13. Bang YJ, Kim YW, Yang HK, et al (2012). Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet, 379, 315-21.
  14. Cunningham D, Allum WH, Stenning SP, et al (2006). Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med, 355, 11-20.
  15. Cunningham D, Starling N, Rao S, et al (2008). Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med, 358, 36-46.
  16. Degiuli M, Calvo F (2006). Survival of early gastric cancer in a specialized European center. Which lymphadenectomy is necessary? World J Surg, 30, 2193-203.
  17. De Vita F, Giuliani F, Orditura M, et al (2007). Adjuvant chemotherapy with epirubicin, leucovorin, 5-fluorouracil and etoposide regimen in resected gastric cancer patients: a randomized phase III trial by the Gruppo Oncologico Italia Meridionale (GOIM 9602 Study). Ann Oncol, 18, 1354-8.
  18. Di Costanzo F, Gasperoni S, Manzione L, et al (2008). Adjuvant chemotherapy in completely resected gastric cancer: a randomized phase III trial conducted by GOIRC. J Natl Cancer Inst, 100, 388-98.
  19. Dikken JL, Jansen EP, Cats A, et al (2010). Impact of the extent of surgery and postoperative chemoradiotherapy on recurrence patterns in gastric cancer. J Clin Oncol, 28, 2430-6.
  20. Jeen YT, Yoon SY, Shin SW, et al (2001). Phase II trial of epirubicin, cisplatin, oral uracil and tegafur, and leucovorin in patients with advanced gastric carcinoma. Cancer, 91, 2288-93.<2288::AID-CNCR1260>3.0.CO;2-8
  21. Jemal A, Bray F, Center MM, et al (2011). Global cancer statistics. CA Cancer J Clin, 61, 69-90.
  22. Kang BW, Kim JG, Chae YS, et al (2011). Pilot study of adjuvant chemotherapy with 3-week combination of S-1 and cisplatin for patients with stage II-IV (M0) gastric cancer. Invest New Drugs, 30, 1671-5.
  23. Karacetin D, Incekara O (2004). A randomized trial of 5-fluorouracil, leucovorin, cisplatin and epirubicin (PELF) versus 5-fluorouracil, leucovorin and etoposide (ELF) given as adjuvant chemotherapy to patients with resected advanced gastric adenocarcinomas. J BUON, 9, 263-7.
  24. Kim DH, Oh CA, Oh SJ, et al (2012). Validation of seventh edition AJCC gastric cancer staging modifications. J Surg Oncol, 105, 26-30.
  25. Kulig J, Kolodziejczyk P, Sierzega M, et al (2010). Adjuvant chemotherapy with etoposide, adriamycin and cisplatin compared with surgery alone in the treatment of gastric cancer: a phase III randomized, multicenter, clinical trial. Oncology, 78, 54-61.
  26. Lim L, Michael M, Mann GB, et al (2005). Adjuvant therapy in gastric cancer. J Clin Oncol, 23, 6220-32.
  27. Moon YW, Jeung HC, Rha SY, et al (2007). Changing patterns of prognosticators during 15-year follow-up of advanced gastric cancer after radical gastrectomy and adjuvant chemotherapy: a 15-year follow-up study at a single korean institute. Ann Surg Oncol, 14, 2730-7.
  28. Aoyama T, Yoshikawa T, Watanabe T, et al (2011). Survival and prognosticators of gastric cancer that recurs after adjuvant chemotherapy with S-1. Gastric Cancer, 14, 150-4.

Cited by

  1. Association between ABCB1 Immunohistochemical Expression and Overall Survival in Gastric Cancer Patients vol.15, pp.16, 2014,
  2. Adjuvant Radiotherapy for Gastric Carcinoma: 10 years Follow-up of 244 cases from a Single Institution vol.15, pp.20, 2014,